Pathophysiology of human tumor xenografts: Aspects of metabolism, physiology, and pharmacokinetics in heterotransplanted human lung and colon tumors

Danish Medical Bulletin

Volumn 44, Issue 4, 1997, Pages 380-385

  Kristjansen, Paul E G ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIATRIZOATE; GEMCITABINE; PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON TUMOR; DRUG DISPOSITION; DRUG METABOLISM; ENERGY METABOLISM; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; LUNG TUMOR; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; TISSUE PERFUSION; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLONIC NEOPLASMS; CORROSION CASTING; HUMANS; HYDROSTATIC PRESSURE; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030819153     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (140)

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. (1991); J Clin Oncol 9: 491-498.
2. Anonymous. The Nobel prizeman. (1931); Lancet ii: 1035
3. Anonymous. Tumour pH. (1992); Lancet 340: 342-343.
4. Bailie CT, Winslet MC, Bradley NJ. Tumour vasculature - a potential therapeutic target. (1995); Br J Cancer 72: 257-267.
5. 31P NMR method. (1984); Biochemistry 23: 6053-6062.
6. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug resistant human leukemic cells. (1987); Cancer Res 47: 5455-5460.
7. Best & Taylor, West JB, (editor). Best and Taylor's Physiological basis of medical practice. 11th ed. Baltimore, London, Los Angeles, Sydney: Williams and Wilkins; 1985;
8. 31P NMR spectroscopy. (1990); NMR in Biomed 3: 178-183.
9. 31P NMR study. (1994); Magn Reson Med 32: 303-309.
10. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. (1987); Science (Washington DC) 235: 1495-1498.
11. Blasberg RG. Prediction of brain tumor therapy response by PET. (1994); J Neurooncol 22: 281-286.
12. Board M, Humm S, Newsholme EA. Maxinum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. (1990); Biochem J 265: 503-509.
13. Board M, Colquhoun A, Newsholme EA. High Km glucose-phosphorylating (glucolcinase) activities in a range of tumor cell lines and inhibition of rates of tumor growth by the specific enzyme inhibitor mannoheptulose. (1995); Cancer Res 55: 3278-3285.
14. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy. (1990); Cancer Res 50: 4478-4484.
15. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. (1991); Cancer Res 51: 6691-6694.
16. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse. (1992); Cancer Res 52: 5110-5114.
17. Broxterman HJ, Pinedo HM. Energy metabolism in multidrug resistant tumor cells: a review. (1991); Journal of Cell Pharmacology 2: 239-247.
18. Busch H. The final common pathway of cancer: presidential address. (1990); Cancer Res 50: 4830-4838.
19. Butler TP, Grantham FH, Gullino PM. Bulk transfer of fluid in the interstitial compartment of mammary tumors. (1975); Cancer Res 35: 3084-3088.
20. Coleman CN. Hypoxia in tumors: A paradigm for the approach to biocchemical and physiologic heterogeneity. A review. (1988); J Natl Cancer Inst 80: 310-317.
21. Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P, Wong D. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. (1994); Ann Oncol 5: 283-285.
22. Daly PF, Cohen JS. Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: A review. (1989); Cancer Res 49: 770-779.
23. 31P MRS of experimental tumours. (1993); NMR Biomed 6: 345-365.
24. de Jong S, Mulder NH, de Vries EGE, Robillard GT. NMR spectroscopy analysis of phosphorous metabolites and the effect of adriamycin on these metabolite levels in an adriamycin-sensitive and -resistant human small cell lung carcinoma cell line. (1991); Br J Cancer 63: 205-212.
25. de Jong S, Holtrop M, de Vries H, de Vries EG, Mulder NH. Increased sensiti vity of an adriamycin-resistant human small cell lung carcinoma cell line to mitochondrial inhibitors. (1992); Biochem Biophys Res Commun 182: 877-885.
26. Desmoulin F, Galons J-P, Canioni P, Cozzone PJ. 31-P nuclear magnetic resonance study of a human colon adenocarcinoma cultured cell line. (1986); Cancer Res 46: 3768-3774.
27. Dunn JF, Frostick S, Adams GE, Stratford IJ, Howells N, Hogan G, Radda GK. Induction of tumour hypoxia by a vasoactive agent. A combined NMR and radiobiological study. (1989); FEBS Letters 249: 343-347.
28. Engelholm SA, Vindeløv LL, Spang-Thomsen M, Brünner N, Tommerup N, Nielsen MH, Hansen HH. Genetic instability of cell lines derived from a single human small cell carcinoma of the lung. (1985); Eur J Cancer 21: 815-824.
29. Eskey CJ, Koretsky AP, Domach MM, Jain RK. 2H-Nuclear magnetic resonance imaging of tumor blood flow: Spatial and temporal heterogeneity in a tissue-isolated mammary adenocarcima. (1992); Cancer Res 52: 6010-6019.
30. 31P NMR. (1993); Proc Natl Acad Sci USA 90: 2646-2650.
31. Eskey CJ, Wolmark N, McDowell CL, Domach MM, Jain RK. Residence time distributions of various tracers in tumors: Implications for drug delivery and blood flow measurement. (1994); J Natl Cancer Inst 86: 93-299.
32. 15O perfusion measurements in the RIF-1 tumor in vivo. (1986); Radiat Res 106: 22-131.
33. Fadness HO, Reed RK, Aukland K. Interstitial fluid pressure in rats measured with a modified wick technique. (1977); Microvascular Research 14: 7-36.
34. Fanciulli M, Paggi MG, Bruno T, Del Carlo C, Bonetto F, Gentile FP, Floridi A. Glycolysis and growth rate in normal and in hexokinase transfected NIH-3T3 cells. (1994); Oncol Res 6: 05-409.
35. 31P phosphorous nuclear magnetic resonance spectroscopy. (1987); Int J Cancer 39: 55-260.
36. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras and sarc oncogenes. (1987); Science (Washington DC) 235: 492-1495.
37. Freyer JP, Schor PL, Jarrett KA, Neeman M, Sillerud LO. Cellular energetics measured by phosphorus nuclear magnetic resonance spectroscopy are not correlated with chronic nutrient deficiency in multicellular tumor spheroids. (1991); Cancer Res 51: 3831-3837.
38. 86Rb as a capillary flow indicator. (1968); Am J Physiol 214: 88-493.
39. Fu KK, Wendland MF, Iyer SB, Lam KN, Engeseth H, James TL. Correlations between in vivo 31P NMR spectroscopy measurements, tumor size, hypoxic fraction and cell survival after radiotherapy. (1990); Int J Radiat Oncol Biol Phys 18: 1341-1350.
40. Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling: Principles and applications. (1983); J Pharmaceutical Sciences 72: 1103-1127.
41. Gerweck LE, Koutcher J, Zaidi ST. Energy status parameters, hypoxia fraction and radiocurability across tumor types. (1995); Acta Oncologica 34: 35-338.
42. Graham RA, Brown TR, Meyer RA. An ex vivo model for the study of tumor metabolism by nuclear magnetic resonance: Characterization of the phosphorus-31 spectrum of the isolated perfused morris hepatoma 7777. (1991); Cancer Res 51: 41-849.
43. Griffiths JR, Bhujwalla Z, Coombes RC, Maxwell RJ, Midwood CJ, Morgan RJ, Nias AHW, Perry P, Prior M, Prysor-Jones RA, Rodrigues LM, Stubbs M, Tozer GM. Monitoring cancer therapy by NMR spectroscopy. (1987); Ann N Y Acad Sci 508: 83-199.
44. Grunewald R, Abbruzzese J, Tarassoff P, Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. (1991); Cancer Chemother Pharmacol 27: 58-262.
45. Gullino PM, Grantham FH, Courtney AH. Utilization of oxygen by transplanted tumors in vivo. (1967a); Cancer Res 27: 1020-1030.
46. Gullino PM, Grantham FH, Courtney AH, Losonczy I. Relationship between oxygen and glucose consumption by transplanted tumors in vivo. (1967b); Cancer Res 27: 1041-1052.
47. Gullino PM. ; Busch H, editors.Methods in cancer research. New York: Academic Press, 1970; Techniques for the study of tumor pathophysiology. p. 45-91.
48. Gullino PM, Grantham FH. Studies on the exchange of fluids between host and tumor. 1. A methods for growing "tissue-isolated" tumors in laboratory animals. (1961); J Natl Cancer Inst 27: 679-693.
49. Gutmann R, Leunig M, Feyh J, Goetz AE, Messmer K, Kastenbauer E, Jain RK. Interstitial hypertension in head and neck tumors in patients: Correlation with tumor size. (1992); Cancer Res 52: 1993-1995.
50. Haberkorn U, Morr I, Oberdorfer F, Bellemann ME, Blatter J, Altman A, Kahn B, van Kaick G. Fluorodeoxyglucose uptake in vitro: Aspects of methos and effects of treatment with gemcitabine. (1994); J Nucl Med 35: 1842-1850.
51. Hamberg LM, Kristjansen PEG, Hunter GJ, Wolf GL, Jain RK. Spatial heterogeneity in tumor perfusion measured with functional computed tomography at 0.05 microliter resolution. (1994); Cancer Res 54: 6032-6036.
52. Hirst DG, Hirst VK, Joiner B, Prise V, Shaffi KM. Changes in tumour morphology with alterations in oxygen availability: further evidence for oxygen as a limiting substrate. (1991); Br J Cancer 64: 4-58.
53. Horsman MR, Chaplin DJ, Brown JM. Tumor radiosensitization by nicotinamide: A result of improved blood perfusion and oxygenation. (1989); Radiat Res 118: 39-150.
54. Horsman MR, Kristjansen PEG, Mizuno M, Christensen KL, Chaplin DJ, Quistorff B, Overgaard J. Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice. (1992); Int J Radiat Oncol Biol Phys 22: 51-454.
55. Imoto H, Sakamura Y, Ohkouchi K, Atsumi R, Takakura Y, Sezaki H, Hashida M. Disposition characteristics of macromolecules in the perfused tissue-isolated tumor preparation. (1992); Cancer Res 52: 4396-4401.
56. Jain RK, Wei J, Gullino PM. Pharmacokinetics of methotrexate in solid tumors. (1979); J Pharmacokinet Biopharm 7: 81-194.
57. Jain RK. Determinants of tumor blood flow: a review. (1988); Cancer Res 48: 2641-2658.
58. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. (1990); Cancer and Metastasis Reviews 9: 53-266.
59. Jain RK. ; Teicher B, editors.Drug resistance in oncology. New York: Marcel Dekker, 1993; Physiological resistance to the treatment of solid tumors.
60. Jain RK. Barriers to drug delivery in solid tumors, (1994); Scientific American 271: 8-65.
61. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. (1988); Cancer Res 48: 7022-7032.
62. Jansson T, Westlin JE, Ahlstroin H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation ? (1995); J Clin Oncol 13: 470-1477.
63. Jensen, PB. Differential sensitivity patterns in small cell lung cancer cell lines: detection and circumvention of resistance to topoisomerase II targeting drugs [Thesis], University of Copenhagen; 1994; 52 p.
64. Jensen PB, Sørensen BS, Sehested M, Grue P, Demant EJF, Hansen HH. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllo-toxins to tumor cells in acidic environments. (1994); Cancer Res 54: 2959-2963.
65. Juliano RL, Ling VA. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. (1976); Biochem Biophys Acta 455: 52-158.
66. Kallinowski F, Vaupel P, Runkel S, Berg G, Fortmeyer HP, Baessler KH, Wagner K, Mueller-Klieser W, Walenta S. Glucose uptake, lactate release, ketone body turnover, metabolic micromilieu, and pH distribution in human breast cancer xenografts in nude rats. (1988); Cancer Res 48: 7264-7272.
67. Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, Vaupel P. Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. (1989); Cancer Res 49: 3759-3764.
68. Kaplan O, Navon G, Lyon RC, Faustino PJ, Straka EJ, Cohen JS. Effects of 2-deoxyglucose on drug-sensitive and drug resistant human breast cancer cells: Toxicity and magnetic resonance spectroscopy studies of metabolism. (1990); Cancer Res 50: 44-551.
69. Karp JE, Broder S. Molecular foundations of cancer: New targets for intervention. (1995); Nature Medicine 1: 09-320.
70. Klimek F, Bannasch P. Isoenzyme shift from glucokinase to hexokinase is not an early but a late event in hepatocarcinogenesis. (1993); Magn Reson Med 27: 96-309.
71. 31P nuclear magnetic resonance. (1988); Cancer Res 48: 917-5921.
72. Koutcher JA, Barnett D, Kornblith AB, Cowburn D, Brady TJ, Gerweck LE. Relationship of changes in pH and energy status to hypoxic cell fraction and hyperthermia sensitivity. (1990); Int J Radiat Oncol Biol Phys 18: 1429-1435.
73. Krarup M, Skovgaard-Poulsen H, Spang-Thomsen M. Cellular radiosensitivity of small cell lung cancer cell lines (1997) Int J Radiat Oncol Biol Phys [in press].
74. 31P magnetic resonance spectroscopy of four human breast cancer xenografts. (1995); Cancer Res 55: 664-1669.
75. 31P magnetic resonance spectroscopy and biochemical analysis. (1990); Cancer Res 50: 880-4884.
76. 31P NMR spectroscopy of human small cell lung cancer in nude mice - Radiobiological aspects [Ph.D. Dissertation]. University of Copenhagen; 1991.
77. Kristjansen PEG, Spang-Thomsen M, Quistorff B. Different energy metabolism in two human small cell lung cancer subpopulations examined by 31P magnetic resonance spectroscopy and biochemical analysis in vivo and in vitro. (1991); Cancer Res 51: 5160-5164.
78. Kristjansen PEG, Pedersen AG, Quistorff B, Spang-Thomsen M. Different early effect of irradiation in brain and small cell lung cancer examined by in vivo 31P-magnetic resonance spectroscopy. (1992); Radiother Oncol 24: 86-190.
79. Kristjansen PEG, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. (1993a); Cancer Res 53: 4764-4766.
80. Kristjansen PEG, Quistorff B, Spang-Thomsen M, Hansen HH. Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts. (1993b); Ann Oncol 4: 57-160.
81. Kristjansen PEG, Roberge S, Lee I, Jain RK. Tissue-isolated human tumor xenografts in athymic nude mice. (1994); Microvascular Research 48: 89-402.
82. Kristjansen PEG, Kristensen CA, Spang-Thomsen M, Quistorff B. Relationship between tumor response and the ratio of nucleotide trophosphates to inorganic phosphate in small cell lung cancer xenografts. (1995); International J Oncology 7: 27-131.
83. Kristjansen PEG, Brown TJ, Shipley LA, Jain RK. Intratumor pharmaco-kinetics, flow resistance, and metabolism during gemcitabine infusion in ex vivo perfused human small cell lung cancer (1996); Clin Cancer Res 2: 59-367.
84. Le Moyec L, Benoist L, De Certaines J. Perspectives d'application de la RMN du phosphore 31 a la surveillance des traitements anticancereux. (1987); Bull Cancer (Paris): 06-515.
85. Lee I, Boucher Y, Jain RK. Nicotinamide can lower tumor interstitial fluid pressure: Mechanistic and therapeutic implications. (1992); Cancer Res 52: 3237-3240.
86. Lee I, Boucher Y, Demhartner TJ, Jain RK. Changes in tumor blood flow, oxygenation and interstitial fluid pressure induced by pentoxofylline. (1994); Br J Cancer 69: 4764-4766.
87. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: Branching patterns and vessel dimensions. (1991); Cancer Res 51: 65-273.
88. Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messmer K, Jain RK. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. (1992); Cancer Res 52: 6553-6560.
89. 18F-fluorodeoxy positron emission tomography in preoperative evaluation of lung cancer. (1994); Lancet 344: 265-1266.
90. Lilly MB, Katholi CR, Ng TC. Direct relationship between high-energy phosphate content and blood flow in thermally treated murine tumors. (1985); J Natl Cancer Inst 75: 85-889.
91. Lund B, Kristjansen PEG, Hansen HH. Clinical and preclinical activity of 2′,2′-diflurodeoxycytidine (gemcitabine). (1993); Cancer Treatment Reviews 19: 5-55.
92. 31P-nuclear magnetic resonance spectroscopy in vivo of six human melanoma xenograft lines: tumour bioenergetic status and blood supply. (1993); Br J Cancer 68: 061-1070.
93. Lyon RC, Cohen JS, Faustino PJ, Megnin F, Myers CE. Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. (1988); Cancer Res 48: 70-877.
94. Mahmood U, Alfieri AA, Ballon D, Traganos F, Koutcher JA. In vitro and in vivo 31P nuclear magnetic resonance measurements of metabolic changes post radiation. (1995); Cancer Res 55: 1248-1254.
95. Murphy E, Gabel SA, Funk A, London RE. NMR observability of ATP: Preferential depletion of cytosolic ATP during ischemia in perfused rat liver. (1988); Biochemistry 27: 26-528.
96. Negendank W. Studies of human tumors by MRS: a review. (1992); NMR Biomed 5: 03-324.
97. Neuwelt EA, Barnett PA, Ramsey FL, Hellström I, Hellström KE, McCormick CI. Dexamethasone decreases the delivery of tumor-specific monoclonal antibody to both intracerebral and subcutaneous tumor xenografts. (1993); Neurosurgery 33: 78-484.
98. Newell K, Franchi A, Pouyssegur J, Tannock I. Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. (1993); Proc Natl Acad Sci USA 90: 1127-1131.
99. 31P NMR spectroscopic study of the effects of gamma-irradiation on RIF-1 tumor cells perfused in vitro. (1995); Magn Reson Med 27: 96-309.
100. Nordsmark M, Crau C, Horsman MR, Jørgensen HS, Overgaard J. Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model. (1995); Acta Oncologica 34: 29-334.
101. Nowel PC. The clonal evolution of tumor cell populations. (1976); Science 194: 3-28.
102. Ohkouchi K, Imoto H, Takakura Y, Hashida M, Sezaki H. Disposition of anticancer drugs after bolus arterial administration in a tissue-isolated tumor perfusion system. (1990); Cancer Res 50: 1640-1644.
103. Okunieff P, McFarland E, Rummeny E, Willett C, Hitzig B, Neuringer L, Suit HD. Effects of oxygen on the metabolism of murine tumors using in vivo phosphorous-31 NMR. (1987); Am J Clin Oncol 10: 75-482.
104. Pantelouris EM. Absence of thymus in a mouse mutant. (1968); Nature 217: 70-371.
105. 13C NMr spectroscopic study of wild type and multidrug resistant Ehrlich Ascites tumor cells. (1993); Oncol Res 5: 19-126.
106. Rasmussen, J. NMR-spektroskopiske studier af energimetabolismen i multi-drug-resistente Ehrlich ascites cancerceller [Ph.D. Dissertation]. Royal School of Pharmacy, Copenhagen, Denmark; 1994; 175 p.
107. 2 cryospectrophotometry in prediction of tumor radioresistance caused by hypoxia. (1989); Int J Radiat Oncol Biol Phys 16: 19-923.
108. 1H NMR studies of rat brain tumor pH and blood flow during acute hyperglycemia: Differential effects between subcutaneous and intracerebral locations. (1989); Magn Reson Med 12: 19-234.
109. Rubin P, Cassarett G. Microcirculation of tumors.I. Anatomy, function, and necrosis. (1966); Clinical Radiology 17: 1640-1644.
110. Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermoken JB, Pinedo HM, Peters GJ. Development and molecular characterization of a 2′,2′ - difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. (1994); Cancer Res 54: 4138-4143.
111. Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumour to "nude" mice. (1969); Acta Pathol Microbiol Scand 77: 58-760.
112. Sauer LA, Stayman JW, Dauchy RT. Arnino acids, glucose, and lactic acid utilization in vivo by rat tumors. (1982); Cancer Res 42: 4090-4097.
113. 14C] glucose. (1995); Metabolism 43: 488-1497.
114. Sensky PL, Prise VE, Tozer GM, Shaffi KM, Hirst DG. Resistance to flow through tissue-isolated transplanted rat tumours located in two different sites. (1993); Br J Cancer 67: 1337-1341.
115. Sevick EM, Jain RK. Viscous resistance to blood flow in solid tumors: Effect of hematocrit on intratumor blood viscosity. (1989a); Cancer Res 49: 3513-3519.
116. Sevick EM, Jain RK. Geometric resistance to blood flow in solid tumors perfused ex vivo: Effects of tumor size and perfusion pressure. (1989b); Cancer Res 49: 3506-3512.
117. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW. Metabolism and disposition of gemcitabine, an oncolytic deoxycytidine analog, in mice, rats, and dogs. (1992); Drug Metab Dispos 20: 49-855.
118. Shtern F. Clinical experimentation in magnetic resonance spectroscopy: a perspective from the National Cancer Institute. (1992); NMR Biomed 5: 25-328.
119. Spang-Thomsen M, Clerici M, Engelholm SA, Vindeløv LL. Growth kinetics and in vivo radiosensitivity in nude mice of two subpopulations derived from a single human small cell carcinoma of the lung. (1986); Eur J Cancer Clin Oncol 22: 49-556.
120. Steel GG. Growth kinetics of tumors. Oxford: Oxford University Press; 1977; 1p.
121. Steel GG, Courtenay VD, Peckham MJ. The response to chemotherapy of a variety of human tumour xenografts. (1983); Br J Cancer 47: 1-13.
122. 31P nuclear magnetic resonance spectroscopy: A review. (1989); Cancer Res 49: 075-4085.
123. Streffer C. ; P.Vaupel RZ, and D.F.Bruley, editors.Oxygen Transport to Tissue XV. New York, NY: Plenum Press, 1994; Glucose-, energy-metabolism and cell proliferation in tumors, p. 327-33.
124. Taghian A, Budach W, Zietman A, Freeman J, Gioioso D, Ruka W, Suit HD. Quantitative comparison between the transplan lability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. (1993); Cancer Res 53: 5012-5017.
125. Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer R, Crawford JW, Frei III E. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. (1990); Science 247: 1457-1461.
126. 31P magnetic resonance spectroscopy spectra of a rat tumour using vasodilators and its relationship to hypotension. (1990); Br J Cancer 62: 53-560.
127. Tozer GM, Priese VE, Bell KM. The influence of nitroc oxide on tumour vascular tone. (1995); Acta Oncologica 34: 73-377.
128. Tufto I, Rofstad EK. Interstitial fluid pressure in human melanoma xenografts. Relationship to fractional tumor water content, tumor size, and tumor volume-doubling time. (1995); Acta Oncologica 34: 361-365.
129. Vaupel P, Fortmeyer HP, Runkel S, Kallinowski F. Blood flow, oxygen consumption, and tissue oxygenation of human breast cancer xenografts in nude rats. (1987); Cancer Res 47: 3496-3503.
130. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. (1989a); Cancer Res 49: 6449-6465.
131. Vaupel P, Okunieff P, Kallinowski F, Neuringer LJ. Correlations between 31P NMR spectroscopy and tissue O2 tension measurements in a murine fibrosarcoma. (1989b); Radiat Res 120: 77-493.
132. Vindeløv L. Cell kinetics, tumour heterogeneity and antineoplastic treatment of small cell carcinoma of the lung. (1985); Clinics in Oncology 4: 5-57.
133. Vogel AW. Tntratumoral vascular changes with increased size of mammary adenocarcinoma - new methods and results. (1965); J Natl Cancer Inst 34: 71-578.
134. Volk T, Jähde E, Fortmeyer HP, Glüsenkamp K-H, Rajewsky MF. pH in human tumour xenografts: effect of intravenous administration of glucose. (1993 ); Br J Cancer 68: 92-500.
135. Warburg O. On the origin of cancer cells. (1956); Science 123: 09-314.
136. WHO. Histological typing of tumors. 2nd ed. Geneva: WHO; 1981;
137. Wu Z, Rivory LP, Roberts MS. Physiological pharmacokinetics of solutes in the isolated perfused rat hindlimb: Characterization of the physiology with changing perfusare flow, protein content, and temperature using statistical moment analysis. (1993); J Pharmacokinetics and Biopharmaceutics 21: 53-688.
138. Yuan F, Leunig M, Berk DA, Jain RK. Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. (1993); Microvascular Research 45: 69-289.
139. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. (1994); Cancer Res 54: 4564-4568.
140. Zlotecki RA, Boucher Y, Lee I, Baxter LT, Jain RK. Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. (1993); Cancer Res 53: 2466-2468.